Accelerate Diagnostics (AXDX) – Investment Analysts’ Weekly Ratings Changes

Posted by ABMN Staff on Dec 31st, 2024

Several analysts have recently updated their ratings and price targets for Accelerate Diagnostics (NASDAQ: AXDX):

12/27/2024 – Accelerate Diagnostics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
12/19/2024 – Accelerate Diagnostics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
12/11/2024 – Accelerate Diagnostics was upgraded by analysts at BTIG Research to a “strong-buy” rating.
12/11/2024 – Accelerate Diagnostics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
12/3/2024 – Accelerate Diagnostics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
11/25/2024 – Accelerate Diagnostics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
11/14/2024 – Accelerate Diagnostics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
11/6/2024 – Accelerate Diagnostics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Accelerate Diagnostics Trading Up 4.5 %

AXDX opened at $1.15 on Tuesday. Accelerate Diagnostics, Inc. has a 12 month low of $0.73 and a 12 month high of $4.24. The stock has a 50-day moving average of $1.62 and a 200 day moving average of $1.54. The firm has a market cap of $28.80 million, a P/E ratio of -0.40 and a beta of 0.56.

Insider Transactions at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience acquired 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the acquisition, the director now directly owns 653,224 shares in the company, valued at $1,025,561.68. The trade was a 44.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 43.60% of the company’s stock.

Hedge Funds Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is currently owned by hedge funds and other institutional investors.

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.